Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
11 hedge funds and large institutions have $2.07M invested in Checkpoint Therapeutics in 2018 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.
267% more funds holding
Funds holding: 3 → 11 (+8)
196% more capital invested
Capital invested by funds: $699K → $2.07M (+$1.37M)
0.09% more ownership
Funds ownership: 0.1% → 0.19% (+0.09%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
+$434K |
| 2 |
Millennium Management
New York
|
+$327K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$269K |
| 4 |
Goldman Sachs
New York
|
+$93.1K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$52.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.26K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OPPM
1
Opus Point Partners Management
New York
| $495K | – | – | – |
|
|
FWM
2
Frontier Wealth Management
Kansas City,
Missouri
| $439K | +$434K | +10,000 | New |
|
|
3
Millennium Management
New York
| $331K | +$327K | +7,539 | New |
|
4
Royal Bank of Canada
Toronto,
Ontario, Canada
| $292K | – | – | – |
|
|
5
Vanguard Group
Malvern,
Pennsylvania
| $272K | +$269K | +6,195 | New |
|
|
6
Goldman Sachs
New York
| $94K | +$93.1K | +2,145 | New |
|
|
PAM
7
Panagora Asset Management
Boston,
Massachusetts
| $53K | +$52.9K | +1,218 | New |
|
|
BCM
8
BlueCrest Capital Management
St Helier,
Jersey
| $45K | +$44.9K | +1,034 | New |
|
9
Morgan Stanley
New York
| $36K | +$35.3K | +814 | New |
|
10
Bank of America
Charlotte,
North Carolina
| $9K | +$8.95K | +206 | New |
|
|
11
UBS Group
Zurich,
Switzerland
| $1K | -$2.26K | -52 | -62% |
|
CKPT Hedge Fund Activity: Q1 2018 in Review
11 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q1 2018, worth a combined $2.07M — up 196% from $699K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CKPT positions and 0 closed out — a net gain of 8 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Frontier Wealth Management, opening a new position worth an estimated $434K. The largest seller was UBS Group, cutting an estimated $2.26K.
- 11 institutional investors held Checkpoint Therapeutics (CKPT) as of Q1 2018, up from 3 in Q4 2017.
- Funds reported $2.07M of Checkpoint Therapeutics stock for Q1 2018, up 196% quarter-over-quarter.
- 8 funds opened new Checkpoint Therapeutics positions in Q1 2018 and 0 closed out, a net change of +8 holders.
- The largest Checkpoint Therapeutics buyer in Q1 2018 was Frontier Wealth Management, an estimated $434K added.
- The largest Checkpoint Therapeutics seller in Q1 2018 was UBS Group, an estimated $2.26K sold.
Based on aggregated 13F filings for Q1 2018.